Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sandoz, Nipro Team Up to Develop, Market Generics
July 18, 2011
- Integration of Nycomed to Accelerate Development of World-class Workforce: Takeda
July 18, 2011
- Korosho Calls For Study on Deregulation of Online OTC Drug Sales in FY2011
July 18, 2011
- Pharmacists Call For Elimination of “No Generics”Option on Prescription Forms: Survey
July 18, 2011
- Problems Can't Be Solved by Meeting Only Once a Year: Mr Matsutani
July 18, 2011
- Regulatory Strategy Consultation to Upgrade Quality of Review, Development: Mr Hirayama of Korosho
July 18, 2011
- Bristol-Myers, AZ Report Breast, Bladder Cancer Findings for Investigational Diabetes Drug
July 18, 2011
- Foreign-affiliated Drug Makers Hire More New Graduates in 2011
July 18, 2011
- Total Review Period for Standard Products Reduced by 4.5 Months to 14.7 Months: PMDA
July 18, 2011
- Positive PII Results for Takeda's TAK-875 Presented at ADA
July 18, 2011
- Ryukaikon Calls For Further Studies on Bar Code Labeling
July 18, 2011
- Committee Starts Discussing Relief System for Victims of Health Hazards Caused by Anticancer Drugs
July 18, 2011
- Positive Results for Central Neuropathic Pain with Lyrica in PIII Trial: Pfizer
July 18, 2011
- SymBio Licenses Rigosertib from Onconova for MDS
July 18, 2011
- Takeda Recalls Actos, Competact in France
July 18, 2011
- Combined with Insulin, Lixisenatide Decreases HbA1c
July 18, 2011
- Hisamitsu to Launch Norspan Tape in Early August Aiming for ¥1.3 Bil. Sales in FY2011
July 18, 2011
- Senju Files for Glaucoma Treatment Seen as Next-generation Strategic Product
July 18, 2011
- Eisai to Accelerate Biomarker Research with Its Subsidiary EIDIA
July 18, 2011
- Roche Returns Overseas Development, Marketing Rights for SGLT-2 Inhibitor to Chugai
July 18, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…